All News

Increasing health insurance enrollment is only one part of the goal of the Affordable Care Act-the law also aims to improve population health and lower healthcare costs, but less attention has been paid to these critical steps.

A quirk in Alaska law allowed Governor Bill Walker to move ahead without support from the legislature.

While growing marketplace enrollment in state-based exchanges is important, retaining enrollees is equally so, and a new report from the Robert Wood Johnson Foundation and the Urban Institute analyzed the renewal process for 6 states.

New research studies show that anti-inflammatory agents can improve survival as well as quality of life in cancer patients.

The combination involves long-acting insulin and a GLP-1 receptor agonist.

America currently has a heroin problem. Can private sector innovations help?

The Office of the National Coordinator for Health Information Technology will be awarding $38 million to 20 organizations in 3 health information technology grant programs working to further nationwide efforts to achieve better care, smarter spending, and healthier people.

Physicians at the Brigham and Women's Hospital have published results from a proof-of-concept study that used mass spectrometry in almost real-time to detect and delineate pituitary tumors from normal tissue.

From 2015 AACC: Fingernail clippings could replace blood draws for diabetes tests, and a new biomarker could speed up tests for gestational diabetes.

All-cause mortality and hospitalization rates and inpatient expenditures among Medicare fee-for-service beneficiaries decreased from 1999 to 2013.

Two inexpensive generic drugs have been shown to reduce breast cancer deaths in postmenopausal women, according to studies published in The Lancet.

Officials say the number of enrollees and their relative good health made it possible to negotiate lower rate increases. However, premium increases are higher in Northern California, where there is less competition.

The California Department of Public Health has announced participation in a pilot project with St. Joseph Health to better understand cancer trends in California.

Drug manufacturers often fail to stick to the 15-day timeframe of reporting serious adverse events to the FDA, a new study in JAMA Internal Medicine reports.

Although hospital readmissions can be difficult to predict, there is a link between the number of discharge medications prescribed to a patient and the risk of 30-day readmission.

Health plans and pharmacy benefits managers are expected to scrutinize the FDA approval to ensure that only those patients who truly need the drug get it.Drugmakers say discounts will cause the price to fall below the $14,600 annual wholesale price listed.

At the ongoing annual ACS NSQIP Conference in Chicago, physicians from the Thomas Jefferson University Hospital in Philadelphia presented a risk score tool that can predict a person's dependence on mechanical ventilation post surgery.

The HHS Secretary told the National Governors Association that she needed their help in fighting substance abuse and in moving the healthcare system from a volume-based to a value-based system.

There is a link between low-value prescribing and graduate medical training, according to a study led by researchers at the Perelman School of Medicine at the University of Pennsylvania and published in the Journal of General Internal Medicine.

The high cost of running a state-based health insurance exchanges created under the Affordable Care Act could lead to states turning over operations to the federal government or joining forces with other states.

This week Bristol-Myers Squibb's phase 3 nivolumab study ended early because renal cell carcinoma patients were experiencing significantly better overall survival, the American Society of Clinical Oncology called for the inclusion of more geriatric patients in trials, and Medicaid expansion states are finding more people enrolling than they planned.

Consolidation among the biggest health insurers in the US continues as Anthem announces it will purchase Cigna for $54 billion after a month of rocky negotiations.

The Sanofi and Regeneron therapy, to be marketed as Praluent, was among the most-anticipated FDA approvals of the year. Late-day reports put pricing at $40 a day wholesale, well above estimates, although insurers will seek discounts.

The FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus genotype 3 infections.

The proposal marks the latest attempt to give consumers more information about the foods they consume.

End-stage cancer patients who were in general the healthiest and most active displayed worse quality of life signs in their last week of life when they were given palliative chemotherapy and there were no benefits to overall survival.

A study published in Nature Medicine has identified a gene signature that can predict cancer patient outcomes across a wide spectrum of malignancies.

Recent surveys have found that public sentiment on drug costs runs high and crosses the political divide. A move this week by the nation's leading oncologists to rein in therapy pricing may be a sign that this is the breakthrough issue of the presidential campaign.

The study has policy implications since Americans 65 and older are eligible for Medicare, and trustees reported this week that the hospital fund will only be solvent until 2030.

Some safety-net hospitals are seeing the best bottom lines in years. But for those in states that refused to expand Medicaid, little has changed.